Drug Trial Radar · NCT03042416
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Jun 29, 2017
Primary completion
Mar 5, 2021
Study completion Jun 2, 2021
Sponsor
- Lead sponsor
- University of AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alberta Health services
- First posted
- Feb 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumor 4. Adult patients with a clinical suspicion of Parkinson's disease 5. Pediatric or Adult patients with primary brain tumors This study will evaluate the biodistribution and safety of 18F-DOPA produced at the Edmonton PET Centre.
Conditions
- Congenital Hyperinsulinism
- Neuroblastoma
- Neuroendocrine Tumors
- Parkinson Disease
- Brain Glioma
Interventions
18F-DOPADrug
18F-DOPA intravenous injection single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immediate safety evaluationTime frame: Within 1 hour of injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alberta Hospital
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.